Related Experiment Video
Updated: Jun 2, 2026
Coronary Artery Ligation and Intramyocardial Injection in a Murine Model of Infarction
Published on: June 7, 2011
Cell-based cardiovascular repair and regeneration in acute myocardial infarction and chronic ischemic
Christian Templin1, Thomas F Lüscher, Ulf Landmesser
1Department of Cardiology, University Hospital Zurich and Cardiovascular Research, Switzerland. Christian.Templin@usz.ch
Insights
Stem cell therapy shows promise for ischemic heart disease, but clinical results lag behind expectations. Optimizing cell therapies by understanding limitations and patient-specific factors is crucial for future success in cardiovascular regenerative medicine.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Cell Biology
Background:
- Ischemic heart disease (IHD) is a leading cause of mortality globally.
- Stem and progenitor cell therapies are a promising frontier for IHD treatment.
- Current clinical applications of stem cell therapy for IHD have not met initial expectations.
Purpose of the Study:
- To review the current evidence on stem and progenitor cells in IHD.
- To explore the properties and regenerative potential of various cell types.
- To discuss strategies for optimizing cell-based therapies for IHD.
Main Methods:
- Literature review of experimental and clinical studies.
- Analysis of stem and progenitor cell properties and functions.
- Evaluation of cell delivery and modulation techniques.
Main Results:
- Experimental studies show potential for stem cells to improve cardiac function post-myocardial infarction.
- Clinical outcomes have not yet matched experimental promise.
- Endothelial progenitor cell number/function is reduced in patients with cardiovascular risk factors.
Conclusions:
- A deeper understanding of limitations in current cell therapies is needed.
- Patient-specific factors, like reduced endothelial progenitor cells, offer avenues for optimization.
- Strategies for cell delivery, homing, and priming are key for advancing cardiovascular cell-based therapies.
Abstract:
Ischemic heart disease is the main cause of death and morbidity in most industrialized countries. Stem- and progenitor cell-based treatment approaches for ischemic heart disease are therefore an important frontier in cardiovascular and regenerative medicine. Experimental studies have shown that bone-marrow-derived stem cells and endothelial progenitor cells can improve cardiac function after myocardial infarction, clinical phase I and II studies were rapidly initiated to translate this concept into the clinical setting. However, as of now the effects of stem/progenitor cell administration on cardiac function in the clinical setting have not met expectations. Thus, a better understanding of causes of the current limitations of cell-based therapies is urgently required. Importantly, the number and function of endothelial progenitor cells is reduced in patients with cardiovascular risk factors and/or coronary artery disease. These observations may provide opportunities for an optimization of cell-based treatment approaches. This review provides a summary of current evidence for the role and potential of stem and progenitor cells in the pathophysiology and treatment of ischemic heart disease, including the properties, and repair and regenerative capacities of various stem and progenitor cell populations. In addition, we describe modes of stem/progenitor cell delivery, modulation of their homing as well as potential approaches to "prime" stem/progenitor cells for cardiovascular cell-based therapies.
